Market Cap 104.30M
Revenue (ttm) 7.01M
Net Income (ttm) -32.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -456.63%
Debt to Equity Ratio 0.00
Volume 47,900
Avg Vol 208,206
Day's Range N/A - N/A
Shares Out 41.72M
Stochastic %K 38%
Beta 0.60
Analysts Strong Sell
Price Target $4.50

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 776 6804
Address:
6303 Waterford District Drive, Suite 215, Miami, United States
DocRosen
DocRosen Aug. 16 at 3:32 PM
$NSPR only a matter of time - who is it going to be?
1 · Reply
Luka2024
Luka2024 Aug. 15 at 12:51 PM
$NSPR terrifying
0 · Reply
LoyalShark
LoyalShark Aug. 15 at 10:21 AM
$NSPR Take into consideration the holding time I have allowed myself to endure and the missed opportunity in being here ---- by far the worst investment in a company I have ever made. Ive lost huge money in some companies but nothing compares to what has been given up to be in this one. Its been a horrific ride.
1 · Reply
Ronnie5isAlive
Ronnie5isAlive Aug. 13 at 5:00 AM
$NSPR $2.50 range still? No surprise here folks. Carry on and see you next week.
1 · Reply
zigsfrd
zigsfrd Aug. 12 at 2:36 PM
$NSPR Sales will constantly improve with FDA approval. The transition to carotid stenting will be much faster than the 5 years it took for cardiac stenting to become the standard of care.
0 · Reply
Threeways
Threeways Aug. 11 at 4:01 PM
$NSPR it may or may not be worth noting. On the conference call and the investor presentation they stated they’ve sold 60,000 stents to date while on linkedin they posted they’ve sold 65,000 to date last week. Maybe they were close to 65k or maybe they sold a bunch; time will tell
1 · Reply
arcuy
arcuy Aug. 10 at 4:25 PM
$NSPR 😎
1 · Reply
Threeways
Threeways Aug. 8 at 3:17 PM
$NSPR trading lower than what orbiMed and Marshall Wace purchased shares at. I wonder what their perception of Starvin Marvin is and if they feel they just blew another 40 million with their idiotic conference call answeres
2 · Reply
zigsfrd
zigsfrd Aug. 7 at 12:54 PM
$NSPR arcuy's post represents exactly what I've believed all along regarding this, that it's a long haul value stock not a meme. Slow boring rise to success.
0 · Reply
arcuy
arcuy Aug. 6 at 11:24 PM
$NSPR I asked ChatGPT to model a realistic adoption scenario for $NSPR. Here’s what it gave me: Fair value estimates per share (based on 5x–7x sales multiple): 📆 2025: $3.00 – $4.20 📆 2026: $17.00 – $23.80 📆 2027: $42.55 – $59.57 📆 2028: $74.00 – $103.60 This is assuming just 10–15% U.S. market share and some international expansion. We’re not even talking full penetration. 💥 If CGuard becomes the standard (as it should), this is going much, much higher. Still under the radar. Not for long. ⏰⏰⏰
2 · Reply
Latest News on NSPR
InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 12:30 PM EDT - 13 days ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript


InspireMD Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 13 days ago

InspireMD Reports Second Quarter 2025 Financial Results


InspireMD Announces Combined Financings of $58 Million

Jul 31, 2025, 8:30 AM EDT - 18 days ago

InspireMD Announces Combined Financings of $58 Million


InspireMD to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:00 AM EDT - 27 days ago

InspireMD to Announce Second Quarter 2025 Financial Results


InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:07 PM EDT - 3 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript


InspireMD Reports First Quarter 2025 Financial Results

May 9, 2025, 7:00 AM EDT - 3 months ago

InspireMD Reports First Quarter 2025 Financial Results


InspireMD to Announce First Quarter 2025 Financial Results

Apr 25, 2025, 9:00 AM EDT - 4 months ago

InspireMD to Announce First Quarter 2025 Financial Results


InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 1:53 PM EDT - 5 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript


InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:20 AM EST - 9 months ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript


InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript


InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript


InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript


InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 11:09 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript


DocRosen
DocRosen Aug. 16 at 3:32 PM
$NSPR only a matter of time - who is it going to be?
1 · Reply
Luka2024
Luka2024 Aug. 15 at 12:51 PM
$NSPR terrifying
0 · Reply
LoyalShark
LoyalShark Aug. 15 at 10:21 AM
$NSPR Take into consideration the holding time I have allowed myself to endure and the missed opportunity in being here ---- by far the worst investment in a company I have ever made. Ive lost huge money in some companies but nothing compares to what has been given up to be in this one. Its been a horrific ride.
1 · Reply
Ronnie5isAlive
Ronnie5isAlive Aug. 13 at 5:00 AM
$NSPR $2.50 range still? No surprise here folks. Carry on and see you next week.
1 · Reply
zigsfrd
zigsfrd Aug. 12 at 2:36 PM
$NSPR Sales will constantly improve with FDA approval. The transition to carotid stenting will be much faster than the 5 years it took for cardiac stenting to become the standard of care.
0 · Reply
Threeways
Threeways Aug. 11 at 4:01 PM
$NSPR it may or may not be worth noting. On the conference call and the investor presentation they stated they’ve sold 60,000 stents to date while on linkedin they posted they’ve sold 65,000 to date last week. Maybe they were close to 65k or maybe they sold a bunch; time will tell
1 · Reply
arcuy
arcuy Aug. 10 at 4:25 PM
$NSPR 😎
1 · Reply
Threeways
Threeways Aug. 8 at 3:17 PM
$NSPR trading lower than what orbiMed and Marshall Wace purchased shares at. I wonder what their perception of Starvin Marvin is and if they feel they just blew another 40 million with their idiotic conference call answeres
2 · Reply
zigsfrd
zigsfrd Aug. 7 at 12:54 PM
$NSPR arcuy's post represents exactly what I've believed all along regarding this, that it's a long haul value stock not a meme. Slow boring rise to success.
0 · Reply
arcuy
arcuy Aug. 6 at 11:24 PM
$NSPR I asked ChatGPT to model a realistic adoption scenario for $NSPR. Here’s what it gave me: Fair value estimates per share (based on 5x–7x sales multiple): 📆 2025: $3.00 – $4.20 📆 2026: $17.00 – $23.80 📆 2027: $42.55 – $59.57 📆 2028: $74.00 – $103.60 This is assuming just 10–15% U.S. market share and some international expansion. We’re not even talking full penetration. 💥 If CGuard becomes the standard (as it should), this is going much, much higher. Still under the radar. Not for long. ⏰⏰⏰
2 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Aug. 6 at 4:57 PM
$NSPR I could have jumped back into $SOFI at $15.00 like I planned - yet here I sit. 1000% my fault.
1 · Reply
streetlove92
streetlove92 Aug. 6 at 2:27 PM
$NSPR Running out of patience, we need to see some results in Q3...
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Aug. 6 at 2:18 AM
$NSPR $2.50!!!! Ahhhhhhh!
3 · Reply
Threeways
Threeways Aug. 5 at 3:53 PM
$NSPR the disappointment today smh. How fn hard is it to say what your internal goal is for the quarter. It’s not a trick question and theres no wrong answer except the one they gave! literally could say our goal is to sell 300 Stents in the US market for XX amount of money. For christ sake its not rocket science!!!!
0 · Reply
Thespectator
Thespectator Aug. 5 at 2:15 PM
$NSPR hate to be right here over and over again😔
1 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Aug. 5 at 1:58 PM
$NSPR A photo of me listening to this morning's conference call.
1 · Reply
LoyalShark
LoyalShark Aug. 5 at 1:38 PM
$NSPR Really rocking it today after that blockbuster conference call. Have to love skirted questions. Have to love the no information approach to creating value in you currency that you keep abusing. Have to love a push out for the 2nd time in a row to 2027. Have to love the POS CEO sitting there spewing a word salad that says absoltuely nothing. Have to love having a team compiled and paid way before launch to be up and running and then consistantly lean on 'it takes time to launch" on the conference call. Tired of the bullshit. 2% yr over yr growth -- WTF? Disappointed in nearly everyway with the call.
0 · Reply
Mt64
Mt64 Aug. 5 at 1:01 PM
$NSPR Per Gleason on the earnings call: double digit procedures with C Guard performed so far in the US. Anyone’s guess as to what double digit might mean. Regardless, strong outlook here for Q3 revenue to be substantially more than Q2.
1 · Reply
Chrisq82
Chrisq82 Aug. 5 at 12:46 PM
$NSPR let’s goooo $4.50!!!!!
0 · Reply
GiveHerTheDD
GiveHerTheDD Aug. 4 at 8:21 PM
$NSPR $1,778 thousand in revenue for Q2 2025 (does not include any CGuard sales in the US)
0 · Reply
GiveHerTheDD
GiveHerTheDD Aug. 4 at 2:38 PM
$NSPR Q2 financials will be lackluster, but the earnings call could be pure gold 🤞
1 · Reply
GaryBx105
GaryBx105 Aug. 4 at 1:21 PM
$NSPR they will need significant market share to breakeven, competing against big players.
1 · Reply